1007232-81-6

Usage

Uses

Used in Pharmaceutical Synthesis:
N-[[[1-Methyl-1-(hydroxymethyl)ethyl]amino]thiocarbonyl]benzamide is used as a key intermediate in the synthesis of pharmaceuticals. Its unique chemical structure allows it to be incorporated into various drug molecules, enhancing their therapeutic properties and effectiveness.
Used in Organic Compounds Synthesis:
This chemical compound is also used in the synthesis of organic compounds. Its reactivity and functional groups make it a valuable building block for creating complex organic molecules with specific properties and applications.
Used in Medicine:
N-[[[1-Methyl-1-(hydroxymethyl)ethyl]amino]thiocarbonyl]benzamide has potential applications in the field of medicine. Its ability to act as a reagent in chemical reactions allows for the development of new drugs and therapeutic agents with improved efficacy and safety profiles.
Used in Agrochemicals:
In the agrochemical industry, N-[[[1-Methyl-1-(hydroxymethyl)ethyl]amino]thiocarbonyl]benzamide can be utilized for the development of new pesticides, herbicides, and other agricultural chemicals. Its reactivity and chemical properties can contribute to the creation of more effective and environmentally friendly products.

Upstream product

• 124-68-5 2-Amino-2-methyl-1-propanol 
• 532-55-8 Benzoyl isothiocyanate 

Downstream Products

• 1007232-83-8 3-{2-[(2-hydroxy-1,1-dimethylethyl)amino]-1,3-thiazol-4-yl}benzonitrile 
• 1007315-24-3 2-fluoro-4-{2-[(2-hydroxy-1,1-dimethylethyl)amino]-1,3-thiazol-4-yl}benzonitrile 

Relevant academic research and scientific papers

1 - Benzoyl -3 - (2 - hydroxy - 1, 1 - dimethyl ethyl) thiourea synthesis method

The invention relates to a method for preparing an organic compound, in particular to a method for compounding 1-benzoyl-3-(2-oxhydryl-1,1-dimethylethyl) thiourea, which comprises the steps: an organic solvent and a raw material, namely 2-amido-2-methylpr

BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE

Benzoxepin compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z1 is CR1 or N; Z2 is CR2 or N; Z3 is CR3 or N; Z4 is CR4 or N; and where (i) X1 is N and X2 is S, (ii) X1 is S and X2 is N, (iii) X1 is CR7 and X2 is S, (iv) X1 is S and X2 is CR7; (v) X1 is NR8 and X2 is N, (vi) X1 is N and X2 is NR8, (vii) X1 is CR7 and X2 is O, (viii) X1 is O and X2 is CR7, (ix) X1 is CR7 and X2 is C(R7)2, (x) X1 is C(R7)2 and X2 is CR7; (xi) X1 is N and X2 is O, or (xii) X1 is O and X2 is N, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Pyrrolidine and related derivatives useful as PR modulators

Compounds of the following structure are described: wherein R1-R6, R11, R12, m, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compou

Tricyclic oxazolidone derivatives useful as PR modulators

Compounds of the following structure are described: wherein R1-R6, R16, m, V, W, X, Y, and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are use

Oxazolidone derivatives as PR modulators

Compounds of the following structure are described: wherein R1, R2, R5, R6, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake or synchronizing estrus.

Oxazolidine derivatives as PR modulators

Compounds of the following structure are described: wherein R1-R6, m, V, W, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a

Imidazolidin-2-one derivatives useful as PR modulators

Compounds of the following structure are described: wherein R1-R6, R10, m, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful f